Invus Global Management, LLC bought $2.0M of LXRX
director, owner at LEXICON PHARMACEUTICALS, INC.. 1,538,462 shares at an average of $1.30, traded Feb 2, 2026, filed Feb 4, 2026.
Score components
- +15RoleDirector
- +25Trade size$2.0M at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +34.6%, 3m +26.0%, 6m +92.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-037644, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 2, 2026 | AGrant or award Common Stockindirect: See Footnotes | +18,553,846 | $1.30 | $24M | 154,734,327 | Feb 4, 2026 |
| Feb 2, 2026 | AGrant or award Common Stockindirect: See Footnotes | +3,846,154 | $1.30 | $5.0M | 7,362,368 | Feb 4, 2026 |
| Feb 2, 2026 | POpen-market purchase Common Stockindirect: See Footnotes | +1,538,462 | $1.30 | $2.0M | 1,538,462 | Feb 4, 2026 |
| Feb 2, 2026 | AGrant or award Series B Convertible Preferred Stockindirect: See Footnotes | +367,145 | $65.00 | $24M | 367,145 | Feb 4, 2026 |
Related signals
Other insiders at LEXICON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | LXRXbuy LEXICON PHARMACEUTICALS, INC. | Raymond Debbane director | $2,980 2,000 shares | +0% | |
| 34Weak | LXRXbuy LEXICON PHARMACEUTICALS, INC. | Raymond Debbane director | $147k 100,000 shares | +6% | |
| 35Weak | LXRXbuy LEXICON PHARMACEUTICALS, INC. | Raymond Debbane director | $220k 150,000 shares | +9% | |
| 41Moderate | LEXICON PHARMACEUTICALS, INC. | Raymond Debbane director | $353k 268,497 shares | +19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.